Novo Nordisk expanded its AI-driven drug discovery capabilities by partnering with the Danish supercomputer Gefion, harnessing computational power for protein engineering and biological modeling. Insilico Medicine released its Nach01 foundation AI model on AWS Marketplace, facilitating generative chemistry tasks with improved accuracy and scalability. These collaborations exemplify the growing integration of advanced computation and AI in biotech for expediting therapeutic development and optimizing pipelines.